文献速递食管与纵隔外科

重症(美国重症肌无力基金会IV-V级)全身型重症肌无力的胸腺切除术:这场博弈真的值得吗?

Thymectomy in severe (Myasthenia Gravis Foundation of America classes IV-V) generalized myasthenia gravis: is the game really worth the candle?
PubMed 文献 · Eur J Cardiothorac Surg · 2023-01-01

回顾性分析76例术前MGFA IV-V级接受胸腺切除术的重症肌无力患者,围术期死亡1例(1.3%)、并发症14例(18.4%),5年累积完全稳定缓解率和改善率分别为20.6%和83.7%,10年分别为66.9%和97.6%。作者结论认为重症患者胸腺切除术围术期结果良好、长期神经学改善满意,尤其适用于年龄≤50岁、MGFA V级和抗AChR抗体阳性者。

要点

  • 76例MGFA IV-V级患者胸腺切除,院内死亡1例(1.3%),术后并发症14例(18.4%)。
  • 5年累积完全稳定缓解率20.6%、改善率83.7%;10年分别为66.9%、97.6%。
  • 年龄≤50岁(P=0.0236)、MGFA V级(P=0.0154)、抗AChR抗体阳性(P=0.0152)者改善率显著更高。

核心结论

  • 重症肌无力严重患者行胸腺切除术围术期结果良好、长期神经学改善满意,尤其年龄小于50岁、MGFA V级和抗AChR抗体阳性者。

研究设计与样本

  • 回顾性收集76例术前MGFA IV级和V级接受胸腺切除术的重症肌无力患者数据。
  • 主要终点包括短期手术结果和长期神经学结果,后者包括达到完全稳定缓解及按MGFA干预后状态标准定义的任何改善。

主要发现

  • 27例(35.5%)男性、49例(64.5%)女性;53例(69.7%)为MGFA IV级,23例(30.3%)为V级。
  • 胸腺切除术经胸骨切开25例(32.9%)、电视辅助胸腔镜手术(VATS)5例(6.6%)、机器人辅助胸腔镜手术(RATS)46例(60.5%)。
  • 中位手术时间120分钟(四分位距:95;148),中位术后住院4天(四分位距:3;6)。
  • 院内死亡1例(1.3%),术后并发症14例(18.4%);病理示胸腺增生/其他良性31例(40.8%)、胸腺瘤45例(59.2%)。
  • 5年累积完全稳定缓解率和改善率分别为20.6%和83.7%,10年分别为66.9%和97.6%。

关键数值与推荐

  • 5年累积完全稳定缓解概率20.6%、改善概率83.7%。
  • 10年累积完全稳定缓解概率66.9%、改善概率97.6%。
  • 年龄≤50岁者改善率P=0.0236,MGFA V级者P=0.0154,抗AChR抗体阳性者P=0.0152。

临床怎么用

  • 作者结论认为对重症肌无力严重患者行胸腺切除术可获得良好围术期结果和满意的长期神经学改善,尤其年龄小于50岁、MGFA V级和抗AChR抗体阳性者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Total thymectomy in addition to medical treatment is an accepted standard therapy for myasthenia gravis (MG). Patients with severe generalized MG present life-threatening events, poor prognosis and higher risk of postoperative myasthenic crisis. The aim of our study is to investigate neurological and surgical results in patients with Myasthenia Gravis Foundation of America (MGFA) class IV and V MG following thymectomy. METHODS: Data on 76 MG patients with preoperative MGFA classes IV and V who underwent thymectomy were retrospectively collected. Primary end points included short-term surgical outcomes and long-term neurological results including the achievement of complete stable remission and any improvement as defined by MGFA Post-Intervention Status criteria. RESULTS: There were 27 (35.5%) males and 49 (64.5%) females; 53 (69.7%) were classified as MGFA class IV and 23 (30.3%) as class V. Thymectomy was performed through sternotomy in 25 (32.9%) patients, Video-assisted thoracic surgery (VATS) in 5 (6.6%) and Robot-assisted thoracic surgery (RATS) in 46 (60.5%). The median operative time was 120 (interquartile range: 95; 148) min. In-hospital mortality was observed in 1 (1.3%) patient and postoperative complications in 14 (18.4%) patients. The median postoperative hospital stay was 4 (interquartile range: 3; 6) days. Pathological examination revealed 31 (40.8%) thymic hyperplasia/other benign and 45 (59.2%) thymomas. Cumulative complete stable remission and improvement probabilities were 20.6% and 83.7% at 5 years and 66.9% and 97.6% at 10 years, respectively. A significant improvement rate was found in patients with age at the time of thymectomy of ≤50 years (P = 0.0236), MGFA class V (P = 0.0154) and acetylcholine receptor antibodies positivity (P = 0.0152). CONCLUSIONS: Thymectomy in patients with severe MG yields good perioperative outcomes and satisfactory long-term neurological improvement, especially for patients younger than 50 years, with MGFA class V and anti-AChR+ MG.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Brascia D, Lucchi M, Aprile V, et al. Thymectomy in severe (Myasthenia Gravis Foundation of America classes IV-V) generalized myasthenia gravis: is the game really worth the candle? Eur J Cardiothorac Surg. 2023. PMID: 37162377. doi:10.1093/ejcts/ezad179

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。